X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218615
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218012
https://www.globenewswire.com/news-release/2023/06/03/2681533/0/en/Cogent-Biosciences-Announces-Positive-Lead-In-Data-from-Ongoing-Phase-3-PEAK-Trial-Evaluating-Bezuclastinib-in-Combination-with-Sunitinib-in-Patients-with-Gastrointestinal-Stromal-.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215843
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213803
https://www.pharmatimes.com/news/smc_accepts_cabometyxopdivo_combo_for_advanced_kidney_cancer_patients_1380746
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213914
https://www.medichem.es/sunitinib-malate-by-medichem-manufactured-in-the-eu-available-worldwide/
https://www.medichem.es/sunitinib-malate-by-medichem-manufactured-in-the-eu-available-worldwide/
https://www.prnewswire.com/news-releases/fda-approves-first-drug-for-fourth-line-treatment-of-advanced-gastrointestinal-stromal-tumors-301060275.html
https://www.biopharmadive.com/news/cabometyx-opdivo-kidney-cancer-exelixis-bristol-myers/576368/
http://www.globenewswire.com/news-release/2020/02/03/1979103/0/en/Immunicum-AB-publ-Announces-Publication-of-Abstracts-for-the-2020-ASCO-SITC-Clinical-Immuno-Oncology-Symposium.html
https://www.medichem.es/curabitur-scelerisque-lacinia-pharetra-sit-amet-5/
http://www.pharmatimes.com/news/keytruda_combo_bags_eu_approval_in_rcc_1300883
http://www.pharmatimes.com/news/immunicums_ilixadencel_successful_in_kidney_cancer_1300226
https://www.biopharmadive.com/news/deciphera-gastrointestinal-cancer-drug-race-blueprint/560808/
https://www.fiercebiotech.com/biotech/deciphera-soars-as-phase-3-cancer-data-tee-up-fda-filing
https://endpts.com/roche-exelixis-cotellic-fizzles-in-pivotal-melanoma-study/
https://www.reuters.com/article/us-merck-co-fda/mercks-keytruda-wins-fda-approval-as-combination-therapy-for-kidney-cancer-idUSKCN1RY0Q3
https://www.businesswire.com/news/home/20190422005185/en/FDA-Approves-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Combination-Inlyta%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://en.prnasia.com/releases/apac/fda-accepts-sbla-and-grants-priority-review-for-bavencio-avelumab-plus-inlyta-axitinib-for-the-treatment-of-advanced-renal-cell-carcinoma-236866.shtml
https://www.reuters.com/article/us-merck-co-keytruda/merck-pfizer-combo-treatment-boosts-kidney-cancer-survival-idUSKCN1Q1037
https://www.fiercebiotech.com/biotech/deciphera-cbo-morl-talks-lines-therapy-for-kinase-inhibitor-ripretinib
https://www.fiercepharma.com/pharma/roche-yanks-tecentriq-kidney-cancer-apps-as-merck-pfizer-speed-toward-approvals
https://www.biopharmadive.com/news/blueprint-posts-impressive-data-for-lead-candidate-but-investor-response/542459/
https://www.reuters.com/article/us-merck-kidney-cancer/merck-kgaa-pfizers-immuno-drug-shown-to-alleviate-kidney-cancer-idUSKCN1LR1IY
http://www.pharmatimes.com/news/nice_u-turn_recommends_ipsens_cabometyx_for_kidney_cancer_1250596
http://www.pharmatimes.com/news/nice_rules_against_first-line_use_of_ipsens_cabometyx_1238556
http://www.pharmatimes.com/news/eu_oks_first-line_use_of_ipsens_cabometyx_1235752
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-16-2018-1526446624.pdf
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002925.jsp&mid=WC0b01ac058004d5c1
http://www.pharmatimes.com/news/five_new_medicines_backed_for_eu_approval_1223972
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002907.jsp&mid=WC0b01ac058004d5c1
https://www.fiercepharma.com/marketing/pfizer-defends-kidney-cancer-position-bavencio-breakthrough
http://www.pmlive.com/pharma_news/fdas_year-end_approvals_take_annual_tally_to_46_1215003
http://www.pharmatimes.com/news/bayers_stivarga_wins_nice_approval_for_gist_1211984
https://seekingalpha.com/article/4099450-bristol-myers-squibb-combination-treatment-end-crossroad
http://www.marketwatch.com/story/bristol-myers-squibb-shares-slip-as-kidney-cancer-drug-trial-falls-short-of-goal-2017-08-15
http://press.pfizer.com/press-release/pfizer-announces-acceptance-regulatory-submissions-us-fda-and-european-medicines-agenc
http://www.fiercebiotech.com/research/cancer-drugs-tarceva-and-sutent-hold-ebola-and-dengue-at-bay-mice
http://www.dddmag.com/news/2016/11/new-drug-beats-standard-therapy-advanced-kidney-cancer?
Market Place
Share 
